Trial Profile
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Crofelemer (Primary)
- Indications Diarrhoea
- Focus Registrational; Therapeutic Use
- Acronyms OnTARGET
- Sponsors Jaguar Health; Napo Pharmaceuticals
- 11 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.
- 11 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Apr 2024.
- 20 Mar 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Mar 2024.